WP
Woodline Partners Portfolio holdings
AUM
$18.9B
This Quarter Return
+9.42%
1 Year Return
+23.37%
3 Year Return
+125.78%
5 Year Return
+185.63%
10 Year Return
–
AUM
$11.8B
AUM Growth
+$11.8B
(+13%)
Cap. Flow
+$899M
Cap. Flow
% of AUM
7.59%
Top 10 Holdings %
Top 10 Hldgs %
12.15%
Holding
744
New
202
Increased
219
Reduced
153
Closed
160
Top Buys
| 1 |
ASML
ASML
|
$125M |
| 2 |
Meta Platforms (Facebook)
META
|
$100M |
| 3 |
STMicroelectronics
STM
|
$92.5M |
| 4 |
MetLife
MET
|
$79.4M |
| 5 |
Gilead Sciences
GILD
|
$77.3M |
Top Sells
| 1 |
TE Connectivity
TEL
|
$161M |
| 2 |
Eli Lilly
LLY
|
$151M |
| 3 |
Marsh & McLennan
MMC
|
$123M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$86.7M |
| 5 |
Electronic Arts
EA
|
$78.6M |
Sector Composition
| 1 | Healthcare | 43.57% |
| 2 | Technology | 17.47% |
| 3 | Industrials | 8.1% |
| 4 | Energy | 6.42% |
| 5 | Financials | 6.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Meta Platforms (Facebook)
META
$1.86T
| $242M | 2.04% | 422,215 +174,625 | +71% | +$100M |
|
|
2
Gilead Sciences
GILD
$140B
| $162M | 1.36% | 1,928,029 +921,537 | +92% | +$77.3M |
|
3
AbbVie
ABBV
$372B
| $160M | 1.35% | 808,736 +58,414 | +8% | +$11.5M |
|
4
Revolution Medicines
RVMD
$7.1B
| $156M | 1.31% | 3,433,713 +142,922 | +4% | +$6.48M |
|
5
Vaxcyte
PCVX
$4B
| $126M | 1.06% | 1,103,945 +397,042 | +56% | +$45.4M |
|
|
6
ASML
ASML
$292B
| $125M | 1.05% | +149,876 | New | +$125M |
|
7
Nuvalent
NUVL
$5.52B
| $122M | 1.03% | 1,193,679 +307,602 | +35% | +$31.5M |
|
8
Permian Resources
PR
$10B
| $118M | 1% | 8,683,996 +1,714,665 | +25% | +$23.3M |
|
9
Ovintiv
OVV
$10.8B
| $114M | 0.96% | 2,984,213 -1,069,527 | -26% | -$41M |
|
10
Keysight
KEYS
$28.1B
| $113M | 0.95% | 712,588 +89,887 | +14% | +$14.3M |
|
11
Danaher
DHR
$147B
| $109M | 0.92% | 393,300 +144,918 | +58% | +$40.3M |
|
12
Aon
AON
$79.1B
| $107M | 0.9% | 309,754 +196,602 | +174% | +$68M |
|
|
13
STMicroelectronics
STM
$24.1B
| $105M | 0.89% | 3,542,770 +3,109,902 | +718% | +$92.5M |
|
|
14
Regeneron Pharmaceuticals
REGN
$61.5B
| $105M | 0.88% | 99,417 -82,480 | -45% | -$86.7M |
|
15
EQT Corp
EQT
$32.4B
| $103M | 0.87% | 2,818,470 +622,034 | +28% | +$22.8M |
|
16
L3Harris
LHX
$51.9B
| $103M | 0.87% | 432,141 +104,065 | +32% | +$24.8M |
|
17
Gulfport Energy Corp
GPOR
$3.06B
| $102M | 0.86% | 675,342 +264,523 | +64% | +$40M |
|
|
18
Eli Lilly
LLY
$657B
| $101M | 0.85% | 114,427 -170,162 | -60% | -$151M |
|
19
Roivant Sciences
ROIV
$8.15B
| $100M | 0.84% | 8,686,476 +685,537 | +9% | +$7.91M |
|
20
Amgen
AMGN
$155B
| $99.2M | 0.84% | 307,950 +15,817 | +5% | +$5.1M |
|
21
Zimmer Biomet
ZBH
$21B
| $99M | 0.83% | 916,927 -275 | -0% | -$29.7K |
|
22
Merck
MRK
$210B
| $96.4M | 0.81% | 848,649 +137,296 | +19% | +$15.6M |
|
23
Chord Energy
CHRD
$6.29B
| $83.8M | 0.71% | 643,518 -110,738 | -15% | -$14.4M |
|
24
Celldex Therapeutics
CLDX
$1.47B
| $79.6M | 0.67% | 2,341,121 +1,583,350 | +209% | +$53.8M |
|
|
25
MetLife
MET
$54.1B
| $79.4M | 0.67% | +962,451 | New | +$79.4M |
|